Abstract: Described herein are methods for the production of extracellular vesicles comprising culturing a population of producer cells in single-cell suspension, wherein the cells are cultured in chemically-defined culture medium, wherein the culture medium lacks animal-derived serum and animal-derived components; and obtaining from the cell culture an extracellular vesicle preparation comprising extracellular vesicles. In certain embodiments, the methods comprise perfusion culturing methods, including single-cell perfusion culturing methods and batch-refeed culturing methods. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.

Abstract: A method of producing a pharmaceutical gel emulsion, wherein the emulsion is an oil-in-water gel emulsion, comprising the steps of forming an oil-in-water emulsion comprising at least one pharmaceutically acceptable oil, at least one aqueous phase, at least one osmotic agent, at least one emulsifying agent, mixing a gelling polysaccharide with the oil-in-water emulsion and allowing the resulting mixture to form the pharmaceutical gel emulsion, optionally mixing an bioactive agent into the pharmaceutical gel emulsion.

Abstract: A domain transcendent file cryptology network includes a first data cryptology node in a first data domain having a first security protocol. A hardware processor of the first data cryptology node executes a first instantiation of a software code to receive a request to transfer a data file from the first data domain to a second data domain having a second, different, security protocol, obtain one or more characteristics of the data file, and generate an authentication tag for the data file based on the characteristic(s). The first instantiation of the software code also encrypts the data file and transmits the encrypted data file, the authentication tag, and a decryption key to a second data cryptology node in the second data domain. The decryption key and the authentication tag enable decryption of the encrypted data file by a second instantiation of the software code on the second data cryptology node.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: A domain transcendent file cryptology network includes a first data cryptology node in a first data domain having a first security protocol. A hardware processor of the first data cryptology node executes a first instantiation of a software code to receive a request to transfer a data file from the first data domain to a second data domain having a second, different, security protocol, obtain one or more characteristics of the data file, and generate an authentication tag for the data file based on the characteristic(s). The first instantiation of the software code also encrypts the data file and transmits the encrypted data file, the authentication tag, and a decryption key to a second data cryptology node in the second data domain. The decryption key to and the authentication tag enable decryption of the encrypted data file by a second instantiation of the software code on the second data cryptology node.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.

Abstract: The invention relates to isolation of novel ?-actin promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters, including rat ?-actin promoter.

Abstract: Described herein are methods for the production of extracellular vesicles comprising culturing a population of producer cells in single-cell suspension, wherein the cells are cultured in chemically-defined culture medium, wherein the culture medium lacks animal-derived serum and animal-derived components; and obtaining from the cell culture an extracellular vesicle preparation comprising extracellular vesicles. In certain embodiments, the methods comprise perfusion culturing methods, including single-cell perfusion culturing methods and batch-refeed culturing methods. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.

Abstract: Devices are described relating to the retaining of surgical tools within the chuck of a reciprocating surgical instrument, such as a reciprocating saw. A securing chuck is disclosed for securing a surgical tool to a reciprocating surgical instrument that comprises a shaft and a securing member. The shaft defines an axis and has a cylindrical bore extending along the axis. The bore is shaped to receive a substantially rounded tool shank. A pair of transverse slots extends into the shaft along a plane passing through the axis for receiving a substantially flattened tool shank. The transverse slots intersect with the cylindrical bore. The securing member is carried by the shaft and is radially movable relative to the bore both inwardly and outwardly to secure the surgical tool in the chuck.

Abstract: The invention relates to isolation of novel ?-actin promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including ?-actin promoter.

Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: Devices are described relating to the retaining of surgical tools within the chuck of a reciprocating surgical instrument, such as a reciprocating saw. A securing chuck is disclosed for securing a surgical tool to a reciprocating surgical instrument that comprises a shaft and a securing member. The shaft defines an axis and has a cylindrical bore extending along the axis. The bore is shaped to receive a substantially rounded tool shank. A pair of transverse slots extends into the shaft along a plane passing through the axis for receiving a substantially flattened tool shank. The transverse slots intersect with the cylindrical bore. The securing member is carried by the shaft and is radially movable relative to the bore both inwardly and outwardly to secure the surgical tool in the chuck.

Abstract: Provided herein are devices and methods for generating microfluidic gradients, including an array of unique microfluidic gradients within an array of microchannels. Fluids within conduits are mixed in an intersection region to generate a mixed flow stream in a source reservoir channel that provides a gradient that varies with axial distance from the intersection region. Microchannels having an inlet connected to the source reservoir channel are configured to provide a microfluidic gradient in the microchannel. An outlet end of the microchannel is connected to a sink reservoir channel. By varying the ratio of fluid flow rates from the fluid conduits, the microchannel gradients are tuned. In this manner, a large number of unique gradients or array of microfluidic gradients is provided, wherein the gradient can be any number of physical or chemical parameters, including concentrations and physical fluid properties.

Abstract: The present invention provides for a method for preparing a thermosensitive hyaluronic acid conjugate comprising the steps of contacting, in any order, a. a predefined amount of hyaluronic acid, b. a predefined amount of one or more thermosensitive polymers having at least one terminal amine moiety and c. a predefined amount of a 1,3,5-triazine (or s-triazine) compound; as well as the conjugates obtainable thereby.

Abstract: Devices are described relating to the retaining of surgical tools within the chuck of a reciprocating surgical instrument, such as a reciprocating saw. A securing chuck is disclosed for securing a surgical tool to a reciprocating surgical instrument that comprises a shaft and a securing member. The shaft defines an axis and has a cylindrical bore extending along the axis. The bore is shaped to receive a substantially rounded tool shank. A pair of transverse slots extends into the shaft along a plane passing through the axis for receiving a substantially flattened tool shank. The transverse slots intersect with the cylindrical bore. The securing member is carried by the shaft and is radially movable relative to the bore both inwardly and outwardly to secure the surgical tool in the chuck.

Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.